Navigation Links
A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
Date:10/14/2009

CHICAGO, Oct. 14 /PRNewswire/ -- ValenTx, Inc. announces the presentation of the first clinical study of their endoluminal approach for the treatment of morbid obesity at the 2009 American College of Surgeons Clinical Congress. The ValenTx procedure is enabled by an implantable and removable sleeve that mimics the mechanisms of gastric bypass surgery without the risks associated with that procedure.

In a collaborative study led by physicians from the University of California San Diego Medical Center and the Imperial College of London, and conducted at the Hospital San Jose de Monterrey in Monterrey, Mexico, 12 patients underwent the implantation of the ValenTx bypass sleeve during a 12-week trial. Patients completing the study achieved an average excess weight loss of 39.5%.

"I'm very excited to present this work at the American College of Surgeons Clinical Congress," said Dr. Bryan J. Sandler, co-author on the study and presenter of the scientific paper. "This initial trial indicates that we can significantly reduce excess weight and positively impact the co-morbidities commonly seen in this patient population."

"We are very honored that the study of our device has been chosen for presentation at the ACS meeting," said James Wright, President of ValenTx. "We see the selection as an affirmation of our clinical focus: to develop a device with the proven therapy mechanisms of a highly effective bariatric procedure, but to enable this in a safer, less invasive manner."

In addition to an oral presentation of the study at the ACS Congress, a video presentation was accepted for the prestigious event. The clinical study will also be published in the Journal of the American College of Surgeons.

"This is very promising data," said Santiago Horgan, M.D., Director of UCSD's Center for the Treatment of Obesity and lead author on the study. "Furthermore, our experience with this device reveals the potential for a completely incision-less and reversible, outpatient procedure in the future."

The study concluded that the ValenTx device could be safely implanted and removed in all patients. In addition to achieving significant weight loss, diabetic patients in the study maintained normal fasting blood glucose levels, without anti hyperglycemic medications during the trial.

About ValenTx

ValenTx, Inc. is developing a less-invasive, implantable medical device to address morbid obesity. The Company's founding principle was to emulate the proven mechanisms of gastric bypass surgery, but with a less invasive, implantable, and removable device. ValenTx was initially funded by leading medical technology venture capital investors, Sapient Capital, EDF Ventures, Kaiser Permanente, Affinity Capital Partners, and T-Gap Ventures. A recent fundraising was led by SV Life Sciences and also included Covidien Ventures. ValenTx is based in Carpinteria, California.

SOURCE ValenTx, Inc.


'/>"/>
SOURCE ValenTx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
2. ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
3. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
4. Unique Hearing Aid Receives Patent Protection
5. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
6. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
7. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
8. Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data
9. Music & Medicine: Unique Collaboration Combines Performing Arts and Science
10. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
11. National Cancer Institute Research Identifies Unique Mechanism of Brostallicins Anti-Tumor Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):